Bridging gaps, building hope, and empowering lives.
Gene Solutions Malaysia was proud to partner with the National Cancer Society Malaysia (NCSM) at the National Cancer Congress Malaysia (NCCM) 2026, contributing to conversations around expanding access to earlier cancer detection across the region.
Guided by the congress theme, “Bridging Gaps, Building Hope, Empowering Lives,” our participation was anchored in a shared vision to help shift the healthcare paradigm from late-stage diagnosis toward earlier detection and more timely intervention.
During the NCCM 2026 Opening Ceremony, Gene Solutions Malaysia received a token of appreciation presented by His Royal Highness Sultan Nazrin Muizzuddin Shah, Sultan of Perak and Royal Patron of NCSM. Mr Lim Chiun Khee, Country Director of Gene Solutions Malaysia, accepted the token on behalf of the company.
This recognition reflects the dedication of the Gene Solutions Malaysia team and reinforces our commitment to supporting clinicians, patients, and the wider healthcare ecosystem through scientific innovation, responsible adoption, and meaningful collaboration.
Throughout the congress and the concurrent NCSM 60’s Wellness Weekend at Sunway Square, our team engaged directly with healthcare professionals, clinical experts, cancer survivors, and members of the public to champion actionable solutions for early detection.
Key highlights included:
- Plenary Session: Dr. Lee Soo Xynn, Medical Science Liaison, led an impactful Plenary Session titled “Beyond One Cancer: Advancing Cancer Screening with Blood- and Swab-Based Detection,” addressing critical pathways to shift the clinical paradigm from late-stage diagnosis to timely intervention.
- Symposium and public talk: Dr. Nalini Devi Verusingam, Medical Science Liaison, presented an insightful Lunch Symposium on “Rethinking Cancer Screening: Are We Screening Enough?” and delivered a Public Talk on “Screening Made Simpler: New Ways to Screen for Women’s and Colorectal Cancers,” empowering both clinicians and individuals to take proactive control of health outcomes.
- Innovation showcase: Gene Solutions Malaysia showcased SPOT-MAS 10, our multi-cancer screening test, which has been granted U.S. FDA Breakthrough Device Designation*. The FDA grants this designation to a limited set of qualifying devices that have the potential to provide for more effective diagnosis of life-threatening or irreversibly debilitating diseases, such as cancer, than current options. This milestone highlights the potential of SPOT-MAS 10’s multi-omics approach to contribute to the earlier detection of cancer.
In addition to SPOT-MAS 10, Gene Solutions Malaysia officially launched methylation-based screening solutions, including SPOT-MAS CRC for colorectal cancer screening and SPOT-MAS Eva for cervical and endometrial cancer screening and triage. Both solutions are now available at NCSM. The launch was officiated by Kolonel Bersekutu (PA) Profesor Madya Dr. Murallitharan Munisamy, Managing Director of NCSM.
We extend our sincere gratitude to the National Cancer Society Malaysia (NCSM) for their leadership in organizing NCCM 2026, and to His Royal Highness for his gracious presence, and to every healthcare professional, partner, and participant who engaged with our team throughout the congress the concurrent Wellness Weekend.
The partnership between NCSM and Gene Solutions Malaysia reflects a shared commitment to addressing gaps in cancer screening and care. By working together, we can help build greater hope for earlier intervention and empower more people across Malaysia to take proactive steps towards their health.
Moving forward, Gene Solutions Malaysia remains committed to working alongside NCSM and the wider medical community to help make earlier cancer detection a more accessible and integrated part of routine care.
*Breakthrough Device Designation is not FDA approval, clearance, or marketing authorization. SPOT-MAS 10 remains subject to future FDA review.
About Gene Solutions Malaysia
Established in 2023, Gene Solutions Malaysia is part of Gene Solutions, a global biotechnology company headquartered in Singapore and dedicated to making advanced genomic solutions more accessible and affordable.
We provide genomic testing and precision healthcare solutions across oncology, reproductive health and women’s health, leveraging Next-Generation Sequencing (NGS), multi-omics and Artificial Intelligence (AI).
The company offers a comprehensive portfolio across oncology, including early cancer screening (SPOT-MAS CRC, SPOT-MAS Lung), multi-cancer early detection (SPOT-MAS 10), and precision oncology (K-TRACK, K4CARE), as well as reproductive and women’s health solutions, including non-invasive prenatal testing (TriSure) and gynecologic cancer screening and triage (SPOT-MAS Eva, EpiHera).
Through collaborations with hospitals, healthcare institutions, laboratories and medical professionals across Malaysia, we are working to bring innovative genomic solutions into clinical practice and contribute to the advancement of precision medicine.
